<DOC>
	<DOCNO>NCT00310804</DOCNO>
	<brief_summary>The present study aim evaluate safety , tolerability immunogenicity three lot Chiron 's cell-derived subunit influenza vaccine healthy adult subject compare conventional egg-derived control vaccine license Europe .</brief_summary>
	<brief_title>Safety Immunogenicity 3 Lots Cell-derived Subunit Influenza Vaccine Compared 1 Lot Egg-derived Subunit Influenza Vaccine Healthy Adults ( &gt; =18 &lt; =60 )</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1 . 18 &lt; 61 year age 2. mentally competent understand nature , scope consequence study 3. able willing give write informed consent prior study entry 4. good health determine : 1. medical history , 2. physical examination , 3. clinical judgment Investigator . 1. unwilling unable give write informed consent participate study 2. participation another clinical trial investigational agent within 90 day prior Visit 1 throughout entire study 3. currently experience acute infectious disease 4. serious disease , , example : 1. cancer , 2. autoimmune disease ( include rheumatoid arthritis ) , 3. advance arteriosclerotic disease complicate diabetes mellitus , 4. chronic obstructive pulmonary disease ( COPD ) require oxygen therapy , 5. acute progressive hepatic disease , 6. acute progressive renal disease , 7. congestive heart failure 5. surgery plan study period 6. bleeding diathesis 7. history hypersensitivity component study medication chemically related substance 8. history anaphylaxis , serious vaccine reaction , allergy vaccine component 9. know suspected impairment/alteration immune function , example resulting : 1. receipt immunosuppressive therapy ( corticosteroid therapy cancer chemotherapy ) , 2. receipt immunostimulants , 3. receipt parenteral immunoglobulin preparation , blood product , and/or plasma derivates within 3 month prior Visit 1 plan full length study , 4. high risk develop immunocompromising disease 10. history drug alcohol abuse 11. laboratoryconfirmed influenza disease within 6 month prior Visit 1 12. receipt influenza vaccine within 6 month prior Visit 1 13. receipt another vaccine within 60 day prior Visit 1 , plan vaccination within 3 week follow study vaccination 14. acute respiratory disease infection require systemic antibiotic antiviral therapy ( chronic antibiotic therapy urinary tract prophylaxis acceptable ) experience fever ( i.e. , axillary temperature â‰¥ 38 degree C ) within 5 day prior Visit 1 15. female , pregnant breastfeed 16. female , refusal use reliable contraceptive method three week follow vaccination 17. plan relocation abroad study period 18. condition , opinion Investigator , might interfere evaluation study objective .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>January 2013</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Flu</keyword>
	<keyword>Cell-Derived</keyword>
	<keyword>Egg-Derived</keyword>
	<keyword>Healthy Adults</keyword>
	<keyword>Safety</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Vaccination</keyword>
</DOC>